Objective: A new library of Thiazolidine-2,4-dione-biphenyl Derivatives derivatives (10a-j) was designed and synthesized. All compounds were characterized by spectral data. Further, these were evaluated for their in vitro anticancer activity.
Methods: The compounds were synthesized as planned in the Scheme-1 and compounds were screened against four human cancer cell lines like cervical cancer (Hela), prostate cancer (PC3), lung cancer cells and breast cancer cells (MDA-MB-231) by employing of MTT assay. Doxorubicin was chosen as positive control.
Result: Most of the compounds showed moderate to good activity. Among them, these compounds 10b and 10d and displayed more potent activity. Predominantly, one compound 10d showed remarkable anticancer activity. Molecular docking studies with EGFR target (PDB ID: 1M17) exhibits compounds 10b and 10d showed desirable molecular interactions with the same residue similar to cocrystal ligand Erlotinib.
Conclusion: This results indicate that these two compounds are well targeted the EGFR active sites and showed more inhibitory effects than the other compounds.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.31557/APJCP.2025.26.1.101 | DOI Listing |
Appl Neuropsychol Adult
January 2025
Faculty Xavier Institute of Engineering, Mahim, India.
In the fields of engineering, science, technology, and medicine, artificial intelligence (AI) has made significant advancements. In particular, the application of AI techniques in medicine, such as machine learning (ML) and deep learning (DL), is rapidly growing and offers great potential for aiding physicians in the early diagnosis of illnesses. Depression, one of the most prevalent and debilitating mental illnesses, is projected to become the leading cause of disability worldwide by 2040.
View Article and Find Full Text PDFHepatology
January 2025
Hepatic Surgery Centre, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, People's Republic of China.
Background And Aims: Immune checkpoint inhibitors (ICIs) have revolutionized systemic hepatocellular carcinoma (HCC) treatment. Nevertheless, numerous patients are refractory to ICIs therapy. It is currently unknown whether diet therapies such as short-term starvation (STS) combined with ICIs can be used to treat HCC.
View Article and Find Full Text PDFRev Soc Bras Med Trop
January 2025
Universidade Federal do Paraná, Departamento de Clínica Médica, Programa de pós-graduação em Medicina Interna e Ciências da Saúde, Curitiba, PR, Brasil.
Cryptococcal disease is the third most common invasive fungal infection in solid organ transplant recipients and is associated with high-morbidity and -mortality rates. Donor-derived Cryptococcus spp. infection typically manifests within the first month post-procedure and has historically been caused by C.
View Article and Find Full Text PDFClin Cancer Res
January 2025
ACTREC, Tata Memorial Centre, Navi Mumbai, Maharashtra, India.
Purpose: Identifying therapeutic targets for Signet Ring Cell Carcinoma (SRCC) of the colon and rectum is a clinical challenge due to the lack of Patient-Derived Organoids (PDO) or Xenografts (PDX). We present a robust method to establish PDO and PDX models to answer address this unmet need. We demonstrate that these models identify novel therapeutic strategies targeting therapy resistance and peritoneal metastasis.
View Article and Find Full Text PDFCien Saude Colet
January 2025
Escola de Enfermagem, Universidade Federal da Bahia. Salvador BA Brasil.
The study aims to explain the discourse of the collective subject of adult and elderly men about the experience of long COVID. Qualitative research, derived from a national multicenter clinical-virtual observatory involving 92 adult men, between 2022 and 2023 in Brazil. IRaMuTeQ software was used (data processing), the Collective Subject Discourse technique (analysis) and socio-anthropological references of the disease experience (interpretation).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!